# US 10,501,471 B1 · Compounds useful for treating cardiovascular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,471 B1
- Document ID: US10501471B1
- Status: Granted
- Kind: B1
- Application number: 16/429,015
- Filed: 2019-06-02
- Granted: 2019-12-10
- Earliest claimed: 2018-11-04
- Assignees: John F. Schmedtje, Jr.
- Applicants: John Frederick Schmedtje, Jr.
- Inventors: John Frederick Schmedtje, Jr.
- Web page: https://patentgrep.com/patent/US10501471B1

## CPC

- C07D 493/04: Ortho-condensed systems
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel compounds and pharmaceutical compositions thereof and methods of using the same for treating cardiovascular diseases.

## Claims

### Claim 1

A compound of formula I, II, or III:
wherein:
R1 is absent;
alternatively, R1 is selected from: (CH2)2O, (CH2)2NH, (CH2)3O, (CH2)3NH, CH2C(═O)O, and CH2C(═O)NH; and,
R2 is selected from: (CH2)2O, (CH2)2NH, (CH2)3O, (CH2)3NH, CH2C(═O)O, CH2C(═O)NH, CH2OC(═O)O, CH2OC(═O)NH, CH2NHC(═O)O, and CH2NHC(═O)NH;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1, wherein the compound is of Formula I:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound of claim 2, wherein:
R1 is absent;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

A compound of claim 2, wherein:
R1 is selected from: (CH2)2O, (CH2)2NH, (CH2)3O, and (CH2)3NH;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

A compound of claim 2, wherein:
R1 is (CH2)2O or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 2)

A compound of claim 2, wherein:
R1 is (CH2)2NH or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 2)

A compound of claim 2, wherein:
R1 is CH2C(═O)O or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 2)

A compound of claim 2, wherein:
R1 is CH2C(═O)NH or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A compound of claim 1, wherein the compound is of Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

A compound of claim 9, wherein:
R2 is selected from: (CH2)2O, (CH2)2NH, (CH2)3O, (CH2)3NH, CH2OC(═O)O, CH2OC(═O)NH, CH2NHC(═O)O, and CH2NHC(═O)NH;
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 9)

A compound of claim 9, wherein:
R2 is CH2C(═O)O or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 9)

A compound of claim 9, wherein:
R2 is CH2C(═O)NH or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A compound of claim 1, wherein the compound is of Formula I:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

A compound of claim 13, wherein:
R1 is absent;
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 13)

A compound of claim 13, wherein:
R1 is selected from: (CH2)2O, (CH2)2NH, (CH2)3O, and (CH2)3NH;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 13)

A compound of claim 13, wherein:
R1 is CH2C(═O)O or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 13)

A compound of claim 13, wherein:
R1 is CH2C(═O)NH or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition, comprising: a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method of treating a disease, comprising: administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1, wherein the disease is a cardiovascular disease.

### Claim 20 (depends on 19)

The method of treating a disease of claim 19, wherein the cardiovascular disease is selected from: coronary artery disease, myocardial infarction, heart failure, cardiac arrrhythmia, electrophysiological disorders of the heart, congenital cardiovascular anomalies, developmental cardiovascular anomalies, inflammatory cardiomyopathy, Kawasaki disease, infectious cardiomyopathy, sudden death/cardiac arrest, atherosclerosis, atherosclerotic cardiovascular diseases, cardiac valve disease, venous insufficiency, cardiac thrombosis, vascular thrombosis, thromboembolism, peripheral arterial disease, aortic aneurysm, aortic dissection, vascular aneurysm, vascular dissection, stroke, systemic hypertension, and pulmonary hypertension.